[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639360":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":51,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":26,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":85,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Citrate anticoagulation","EXPERIMENTAL","Participants will undergo postdilution hemodiafiltration using regional citrate anticoagulation with 8% trisodium citrate infusion and calcium substitution according to ionized calcium measurements",[13],"Drug: Regional citrate anticoagulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Heparin anticoagulation","ACTIVE_COMPARATOR","Participants will undergo postdilution hemodiafiltration using standard unfractionated heparin anticoagulation according to routine clinical protocol.",[19],"Drug: Unfractionated heparin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Regional citrate anticoagulation","Regional citrate anticoagulation using 8% trisodium citrate infusion during postdilution hemodiafiltration with calcium substitution adjusted according to ionized calcium levels.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Unfractionated heparin","Standard unfractionated heparin anticoagulation administered according to routine clinical protocol during postdilution hemodiafiltration.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Milena MD Andonova","CONTACT","+38615228123","milena.andonova@kclj.si",[38],{"facility":5,"status":26,"city":39,"state":26,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Ljubljana","1000","Slovenia","SI",{"type":44,"coordinates":45},"Point",[46,47],14.50513,46.05108,{"lat":47,"lon":46},[50],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Milena Andonova","Principal Investigator, Department of Nephrology","100639360","comparison-of-citrate-and-heparin-anticoagulation-during-postdilution-hemodiafiltration-100639360",false,"NCT07618858","Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration","Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial","CITRA-HDF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End-stage kidney disease requiring maintenance postdilution hemodiafiltration\n* Stable chronic hemodialysis treatment three times weekly\n* Functional arteriovenous fistula\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation therapy\n* Dual antiplatelet therapy\n* Significant coagulopathy\n* Active bleeding\n* Acute kidney injury","ALL","18 Years",{"count":66,"type":67},20,"ESTIMATED","INTERVENTIONAL",[70],"NA","This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.\n\nThe primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).\n\nSecondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.\n\nTwenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.\n\nThe study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.",[73,74,75,76],"End-Stage Kidney Disease","Hemodiafiltration","Chronic Hemodialysis","Renal Failure",[9,15,74,78,79,80,81,23,82,83,84],"Dialysis","Biocompatibility","Beta-2 microglobulin","Complement activation","Chronic dialysis","Thrombin-antithrombin complex","Platelet factor 4","NOT_YET_RECRUITING","2026-05-27",{"date":88,"type":89},"2026-06-01","ACTUAL",{"date":91,"type":67},"2026-06-05",{"date":93,"type":67},"2027-04-01",{"name":5,"class":6},1]